Interní Med. 2003; 5(5): 240-242

Význam terapeutického testu v diagnostice refluxní choroby jícnu

prof. MUDr. Aleš Hep CSc, MUDr. Jiří Dolina
III. interní klinika gastroenterologická, FN Brno-Bohunice

Keywords: therapeutic test, gastro-oesophageal reflux disease, omeprazol, pyrosis.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hep A, Dolina J. Význam terapeutického testu v diagnostice refluxní choroby jícnu. Interní Med. 2003;5(5):240-242.

Terapeutický test refluxní choroby jícnu je určen zejména pro první linii s cílem odlišit skupinu nemocných, která nevyžaduje další vyšetření specialistou a zejména vyšetření endoskopické. Většinou je používán omeprazol 2 × 20 mg po dobu dvou týdnů. Hodnocení efektivity testu je založeno pouze na hodnocení omezeného počtu subjektivních příznaků, především pyrózy. Endo­skopie by měla být provedena vždy, pokud jsou přítomny alarmující příznaky jako nechutenství, váhový pokles, anémie, při přetrvávajících nebo výrazných potížích a ve věku nad 50 let. Spolehlivost terapeutického testu je samozřejmě limitována.

Significance of Therapeutic test in diagnosis of Gastro-Oesophageal Reflux Disease

Therapeutic test of gastro-oesophageal reflux is intended for front line diagnostic with the aim to find patients who do not need examination by a specialist, mainly endoscopy. Usually, omeprazol 20 mg twice a day is given for two weeks. Assessment of effectivity of treatment is only on several subjective symptoms, mainly pyrosis. Endoscopy should be done always, when alarming signs are present, such as loss of appetite, weight loss, anemia, persistent or pronounced signs, or in patients above 50 years. Reliability of therapeutic test is clearly limited.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bate CM, Riley SA, Chapman RW, et all. Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 1: 75-77. Go to original source... Go to PubMed...
    2. Bruno G, Andreozzi P, Bagalino A, et all. Gastric asthma: A vagally-mediated disease. Int J Immunopathol Pharmacol 1997; 3: 195-204. Go to original source...
    3. Cucchiara S, Franco MT, Terrin G, et al. Role of drug therapy in the treatment of gastro-oesophageal reflux disorder in children. Paediatr Drugs 2000; 4: 263-272. Go to original source... Go to PubMed...
    4. Deviere J. Satelit symposium, 8. UEGW Brussels 2000.
    5. Eggleston A, Wigerinck A, Huijghebaert S, et al. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: A clinical database analysis. GUT 1998; 1: 13-16. Go to original source... Go to PubMed...
    6. Egler M, Geursen R. Economic studies of healthcare and their implications. Drugs Made Ger 1998; 4: 87-90.
    7. Ekstrom T. The importance of gastro-oesophageal reflux as a trigger factor in asthma. Clin Astma Rev 1998; 4: 161-174.
    8. Fennerty MB. Use of antisecretory agents as a trial of therapy. GUT 2002; 50 (suppl. 4): 63-66. Go to original source... Go to PubMed...
    9. Fernandez-Bustillo JM, Bautista A, Pavon P, et al. Experience with omeprazol in thirty cases of gastroesophageal reflux. Rev Esp Pediatr 1999; 55: 408-415. Go to original source...
    10. Galmiche JP. Gastro-oesophageal reflux disease: From pathophysiology to treatment. Res Clin Forums 1998; 2: 11-18.
    11. Henry JP, Lenaerts A, Ligny G. Diagnosis and treatment of adult's gastroesophageal reflux: Orientations suggested by the French and Belgium consensus conferences. Rev Med Brux 2001; 1: 27-32.
    12. Ing AJ. Interstitial lung disease and gastroesophageal reflux. Am J Med 2001; 111 (suppl. 1): 41S-44S. Go to original source... Go to PubMed...
    13. Ing AJ, Ngu MC, Breslin ABX. Obstructive sleep apnea and gastroesophageal reflux. AM-J-MED 2000; 108 (4 SUPPL. 1): 120-125. Go to original source... Go to PubMed...
    14. Kanber Y, Kalayci AG. Gastroesophageal reflux in children. Ondokuz Mayris Univ Tip Derg 2001; 1: 57-64.
    15. McDougall NI, Johnston BT, Collins JSA, et al. Three- to 4.5-year prospective study of prognostic indicators in gastro- oesophageal reflux disease. Scand J Gastroenterol 1998; 10: 1016-1022. Go to original source... Go to PubMed...
    16. Pashankar D, Blair GK, Israel DM. Omeprazole maintenance therapy for gastroesophageal reflux disease after failure of fundoplication. J Pediatr Gastroenterol. Nutr 2001; 2: 145-149. Go to original source... Go to PubMed...
    17. Quigley EMM. Non-erosive reflux disease: Part of the spectrum of gastro-oesophageal reflux disease, a component of functional dyspepsia, or both? Eur J Gastroenterol Hepatol 2001; 13 (Suppl. 1): S13-S18.
    18. Sontag SJ. Gastroesophageal reflux and asthma. Am J Med 1997; 5: 84S-90S. Go to original source... Go to PubMed...
    19. Tebaldi M, Heading RC. Quality of life assessment in reflux disease. Eur J Gastroenterol hepatol 1998; 6: 451-454. Go to original source... Go to PubMed...
    20. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 10: 965-973. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.